- Home » News and EventsPage 12
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
Jan 7, 2019
Catalent, Inc. today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.
Catalent Invests $14 Million To Expand Biologics Packaging Capabilities Following Twentieth Commercial Drug Approval At Bloomington, Indiana Site
Dec 3, 2018
Catalent today announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.
Continuous Bioprocessing And Cell Line Development To Be Presented By Catalent At The Waterside Conference™
Nov 6, 2018
Catalent today announced that two of its experts have been invited to speak at the upcoming Waterside Conference.
Phase-Appropriate Validation Of Bioassays To Be Presented By Catalent At WCBBA Workshop
Oct 15, 2018
Catalent today announced that one of its scientific experts will host a workshop during KNect365 Life Sciences’ annual Well Characterized Biologics & Biological Assays conference (WCBBA).
Catalent Biologics Expert to Discuss Assay Automation at IDDST
Aug 9, 2018
Catalent today announced that Christopher Hepler, Group Leader, Biologics Analytical Services, Catalent Biologics has been invited to speak at the upcoming 16th Annual Congress of International Drug Discovery Science & Technology.
Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform
Jul 10, 2018
Catalent Pharma Solutions and Berkeley Lights, Inc., a leader in digital cell biology, today announced Catalent Biologics will adopt BLI’s Beacon® optofluidic platform to accelerate its cell line development workflow.
Catalent Biologics Appoints New General Manager for Madison, Wisconsin
Jun 26, 2018
Catalent Pharma Solutions today announced that Graham Brearley, Ph.D., has been appointed as General Manager of the company’s Madison, Wisconsin facility.
Catalent Biologics Supports New Methamphetamine Treatment
May 31, 2018
Catalent today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200.
Catalent Biologics and Valerius Biopharma to Collaborate on Biosimilars
May 14, 2018
Catalent and Valerius Biopharma AG, a Swiss biopharmaceutical company, today announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.